Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ: HCM )

16.11 +0.78 (+5.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
Via Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier. 
Via Investor's Business Daily
Rocket Pharmaceuticals Stock Sees Improved Price Strength
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78 
Via Investor's Business Daily
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
Virtual Investor Conference on November 8th and 9th, 2023 
From Virtual Investor Conferences
Via GlobeNewswire
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Sarepta Therapeutics Stock Showing Rising Relative Strength
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — 
From HUTCHMED (China) Limited
Via GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may... 
Via Talk Markets
Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study
HUTCHMED (China) Limited's (NASDAQ: ​HCM) pivotal Phase 3 trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints... 
Via Benzinga
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers Save Foods, Inc. (NASDAQ: SVFD) shares surged 76.6% to $1.13 in pre-market trading after gaining 15% on Friday. 
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.